An NDA (New Drug Application) is the formal submission drug sponsors file with the FDA to seek approval to market a new pharmaceutical in the U.S. The FDA has 60 days to decide whether to accept it for review, and once accepted, the review can take 6 to 10 months.
The NDA is the formal submission that lets drug sponsors seek approval to market a new drug in the U.S.
The NDA is the formal submission that lets drug sponsors seek approval to market a new drug in the U.S.
NDA stands for New Drug Application—the formal process drug developers use to ask the FDA for permission to sell a new pharmaceutical in the U.S. Don’t confuse this with the unrelated NDA used for confidentiality agreements in business. This NDA is all about proving a drug is safe and effective for its intended use.
Quick Fix Summary
If you're trying to understand how the FDA's New Drug Application (NDA) works right now, here's the deal: the NDA is the formal submission that lets drug sponsors seek approval to market a new drug in the U.S. It has to include everything from animal studies to full clinical trial data. The FDA gets 60 days to decide whether to accept it for review. Once accepted, the review can take 6 to 10 months. From IND to final approval, the whole process usually takes about nine years.
An NDA is the formal request drug developers file with the FDA to get a new drug approved for sale in the United States.
An NDA is the formal request drug developers file with the FDA to get a new drug approved for sale in the United States.
An NDA is the formal request drug developers file with the FDA to get a new drug approved for sale in the United States. It’s not the same as the earlier Investigational New Drug (IND) application, which only covers early safety testing. The NDA is the full package—clinical trial results, manufacturing details, proposed labels, and safety data—all designed to prove the drug works and is safe for its intended use.
Drug sponsors file an NDA to give the FDA complete evidence that a drug is safe, effective, and consistently manufactured.
Drug sponsors file an NDA to give the FDA complete evidence that a drug is safe, effective, and consistently manufactured.
Drug sponsors file an NDA to give the FDA complete evidence that a drug is safe, effective, and consistently manufactured. The application must show that the benefits outweigh the risks for the target population. The FDA uses this mountain of data to decide whether to approve the drug, reject it, or ask for more information. This process is governed by the Federal Food, Drug, and Cosmetic Act, which got an update in 2024 to include digital health tools used in drug development.
NDA vs. IND: Key Differences
The IND (Investigational New Drug) application comes first, filed before any human testing to prove initial safety and allow early clinical trials. The NDA, on the other hand, is submitted after Phase 3 trials—often involving hundreds or thousands of participants—and includes the complete dataset needed for approval. Where the IND is about exploration and safety, the NDA is about confirmation and getting ready for the market. The NDA also has to include a detailed manufacturing plan to guarantee consistent drug quality.
The NDA process follows a strict timeline set by FDA rules, typically taking 6 to 10 months for review after acceptance.
The NDA process follows a strict timeline set by FDA rules, typically taking 6 to 10 months for review after acceptance.
The NDA process follows a strict timeline set by FDA rules. Here’s how it works in 2026:
- Preparation Phase (Months –2 to 0): Finalize all clinical data, manufacturing protocols, and labeling. Hold end-of-Phase 3 meetings with the FDA to make sure everyone’s on the same page. This stage sometimes includes filing a Biologics License Application (BLA) for biologics, which has a similar but separate process.
- NDA Submission: Send the complete application through the FDA’s Electronic Regulatory Submission and Review (ERSR) portal. Double-check that all modules are complete and validated—Module 1 for admin data, Module 2 for summaries, Module 5 for clinical reports.
- FDA Filing Decision (Days 0–60): The FDA has 60 days to decide if the NDA is “fileable.” If not, they send a Refuse-to-File (RTF) letter explaining why. Back in 2025, the FDA reported that about 12% of NDAs got RTFs due to missing safety data or weak manufacturing details (FDA 2025 Annual Report).
- Review Phase (Months 6–10): FDA reviewers dig into clinical efficacy, safety, label accuracy, and manufacturing compliance. They might consult external experts through advisory committees. The review team puts together a Cumulative Analytic Assessment (CAA), a big-picture report of all their findings.
- Decision (Month 10): The FDA makes one of three calls:
- Approval: The drug can hit the market.
- Approvable: There are issues, but they can be fixed with label or manufacturing tweaks.
- Not Approvable: Major problems mean more trials or studies are needed.
If your NDA gets rejected, you can request a Type A meeting, submit a major amendment, or pursue accelerated approval for serious conditions.
If your NDA gets rejected, you can request a Type A meeting, submit a major amendment, or pursue accelerated approval for serious conditions.
If your NDA gets rejected, don’t throw in the towel. There are three clear ways to move forward:
- Request a Type A Meeting: Within 14 days of an RTF or Approvable letter, ask the FDA for a meeting to clarify what’s missing and agree on next steps. These meetings get priority and usually happen within 30 days.
- Submit a Major Amendment: Fix the issues with new data—maybe more clinical trials or updated safety reports—and resubmit the NDA. Each major amendment can add up to six months to the review clock.
- Pursue Accelerated Approval for Serious Conditions: If the drug treats a life-threatening or severely debilitating illness, look into the Accelerated Approval pathway. It lets approval happen based on surrogate endpoints, with final confirmation required after the fact.
Most NDA problems can be avoided with careful planning, early FDA meetings, and validated electronic systems for data capture.
Most NDA problems can be avoided with careful planning, early FDA meetings, and validated electronic systems for data capture.
Most NDA problems can be avoided with careful planning. Start early and talk to the FDA often. Use the Type B meeting program to get guidance at key points—especially after Phase 2 and before submitting the NDA. Make sure your clinical trials follow FDA feedback and include diverse populations, as required by the 2024 Diversity in Clinical Trials Guidance. For studies that don’t need full IRB oversight, you might explore what type of studies do not need IRB approval to streamline the process.
Use validated electronic systems for data capture and submission to dodge formatting errors. Run a mock NDA review with an outside consultant who knows FDA expectations. And don’t forget a strong pharmacovigilance plan to track post-market safety—this is now a big part of the NDA and subject to FDA audits within two years of approval.
For context, the average time from IND to NDA approval has been about 8.9 years over the last decade, with biologics taking a bit longer than small molecules (FDA 2023 NDA/BLA Approval Data). Plan with this timeline in mind to boost your chances of first-cycle approval.
The FDA’s own data shows that NDAs filed with complete chemistry, manufacturing, and controls (CMC) sections are 30% more likely to avoid Refuse-to-File letters (FDA CMC Best Practices).
The purpose of an NDA is to provide the FDA reviewer adequate data to ensure the safety and efficacy of the drug, labeling, and manufacturing process.
The purpose of an NDA is to provide the FDA reviewer adequate data to ensure the safety and efficacy of the drug, labeling, and manufacturing process.
Why do drug sponsors submit an NDA? The purpose is simple: to give the FDA everything it needs to confirm a drug is safe, effective, and properly labeled. Once submitted, the FDA has 60 days to decide whether to review the application or reject it due to missing information.
The NDA is much more comprehensive than the IND and provides detailed information about the drug.
The NDA is much more comprehensive than the IND and provides detailed information about the drug.
What’s the difference between an NDA and IND? The IND (Investigational New Drug) application comes first, covering early safety testing. The NDA, though, is the full package—clinical trial results, manufacturing details, proposed labels, and safety data. Honestly, this is the most important distinction in the whole approval process.
After NDA approval, the FDA review team decides if the application is complete before moving forward.
After NDA approval, the FDA review team decides if the application is complete before moving forward.
What happens after an NDA gets approved? The FDA review team first checks if the application is complete. If it isn’t, they can refuse to file it. If it is complete, they have 6 to 10 months to make a decision on whether to approve the drug.
NDAs are submitted to the FDA after Phase 3 clinical trials.
NDAs are submitted to the FDA after Phase 3 clinical trials.
When do drug sponsors submit an NDA? It happens after Phase 3 studies—typically involving several hundred to about 3,000 people. The pre-NDA period is when the FDA and drug sponsors usually meet to finalize everything before the formal submission.
FDA NDA review typically lasts 6 to 10 months after acceptance.
FDA NDA review typically lasts 6 to 10 months after acceptance.
How long does FDA approval take? The NDA review stage itself usually lasts 6 to 10 months once accepted. Add that to the earlier development stages, and you’re looking at about nine years total from IND to final approval.
NDA stands for non-disclosure agreement, a legally binding contract protecting confidential information.
NDA stands for non-disclosure agreement, a legally binding contract protecting confidential information.
What does NDA stand for in business contexts? It stands for non-disclosure agreement—a legally binding contract where parties agree not to share sensitive information they obtain. You’ll see these in corporate settings all the time.
The FDA’s New Drug Application (NDA) is how drug sponsors formally propose approval for a new pharmaceutical.
The FDA’s New Drug Application (NDA) is how drug sponsors formally propose approval for a new pharmaceutical.
What exactly is new drug approval? It’s the process through which the FDA reviews and potentially approves a new pharmaceutical for sale and marketing in the U.S. The NDA is the formal vehicle for this proposal.
The FDA protects public health by ensuring drug safety, efficacy, and manufacturing standards.
The FDA protects public health by ensuring drug safety, efficacy, and manufacturing standards.
What does the FDA actually do? The agency’s mission is to protect public health by ensuring the safety, efficacy, and security of human and veterinary drugs, biological products, and medical devices. They also oversee food safety, cosmetics, and radiation-emitting products.
Pending New Drug Applications are generally not public until acknowledged or disclosed by the FDA.
Pending New Drug Applications are generally not public until acknowledged or disclosed by the FDA.
Are new drug applications public? Not usually. Current regulations prohibit public disclosure of pending NDAs or BLAs unless the FDA has already acknowledged them. Most information in these applications remains confidential until approval.
The four stages of drug approval are Discovery & Development, Preclinical Research, Clinical Research, and FDA Review.
The four stages of drug approval are Discovery & Development, Preclinical Research, Clinical Research, and FDA Review.
What are the four stages of drug approval? They break down like this:
- Phase I: Discovery & Development
- Phase II: Preclinical Research
- Phase III: Clinical Research
- Phase IV: FDA Review
- Phase V: FDA Post-Market Safety Monitoring
There are three clinical trial phases before FDA approval.
There are three clinical trial phases before FDA approval.
How many trial phases come before FDA approval? Three. Phase 1 tests safety, Phase 2 looks at efficacy and side effects, and Phase 3 confirms effectiveness in larger populations. Only after these three phases can a drug sponsor submit an NDA.
NDA approval means the sponsor has submitted enough evidence for the FDA to consider marketing approval.
NDA approval means the sponsor has submitted enough evidence for the FDA to consider marketing approval.
What exactly is NDA approval? It’s the point when a drug sponsor believes they’ve gathered enough evidence on safety and effectiveness to meet FDA requirements. At that point, they formally submit the NDA to the FDA for consideration.
FDA reviewers decide whether to approve an NDA after reviewing labeling and manufacturing facilities.
FDA reviewers decide whether to approve an NDA after reviewing labeling and manufacturing facilities.
Who actually decides FDA approval? FDA reviewers do. They examine the drug’s professional labeling, ensure proper information reaches healthcare professionals and consumers, and inspect manufacturing facilities. Then they either approve the application or issue a response letter.
FDA approval time varies from one week to eight months depending on the application type.
FDA approval time varies from one week to eight months depending on the application type.
How long does FDA approval take? It depends entirely on what you’re submitting. Self-registrations might take a week, while a 510(k) application could take months. For Premarket Approval (PMA) applications, expect it to drag out closer to eight months.
The NDA application formally proposes FDA approval for a new pharmaceutical’s sale and marketing.
The NDA application formally proposes FDA approval for a new pharmaceutical’s sale and marketing.
Why do drug sponsors submit an NDA? Because it’s the formal vehicle through which they propose that the FDA approve a new pharmaceutical for sale and marketing in the U.S. All the data from animal studies and human clinical trials during the IND phase gets rolled into this final submission.
